Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy

• Published in: Frontiers in immunology Vol. 14; p. 1119371
• Main Authors: Mastelic-Gavillet, Beatris, Sarivalasis, Apostolos, Lozano, Leyder Elena, Lofek, Sebastien, Wyss, Tania, Melero, Ignacio, de Vries, I. Jolanda M., Harari, Alexandre, Romero, Pedro, Kandalaft, Lana Elias, Viganó, Selena
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 10.02.2023
• Subjects: cancer vaccine; chemotherapy; Dendritic Cells - immunology; Female; Humans; Immunology; Immunotherapy; Monocytes; Neoplasm Recurrence, Local; ovarian cancer; Ovarian Neoplasms - drug therapy; TLR3; cancer vaccine; ovarian cancer; chemotherapy; TLR3; DC
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2023.1119371

The use of circulating cDC1 to generate anti-cancer vaccines is among the most promising approaches to overcome the limited immunogenicity and clinical efficacy of monocyte-derived DC. However, the recurrent lymphopenia and the reduction of DC numbers and functionality in patients with cancer may represent an important limitation of such approach. In patients with ovarian cancer (OvC) that had received chemotherapy, we previously showed that cDC1 frequency and function were reduced. We recruited healthy donors (HD, n=7) and patients with OvC at diagnosis and undergoing interval debulking surgery (IDS, n=6), primary debulking surgery (PDS, n=6) or at relapse (n=8). We characterized longitudinally phenotypic and functional properties of peripheral DC subsets by multiparametric flow cytometry. We show that the frequency of cDC1 and the total CD141+ DC capacity to take up antigen are not reduced at the diagnosis, while their TLR3 responsiveness is partially impaired in comparison with HD. Chemotherapy causes cDC1 depletion and increase in cDC2 frequency, but mainly in patients belonging to the PDS group, while in the IDS group both total lymphocytes and cDC1 are preserved. The capacity of total CD141 DC and cDC2 to take up antigen is not impacted by chemotherapy, while the activation capacity upon Poly(I:C) (TLR3L) stimulation is further decreased. Our study provides new information about the impact of chemotherapy on the immune system of patients with OvC and sheds a new light on the importance of considering timing with respect to chemotherapy when designing new vaccination strategies that aim at withdrawing or targeting specific DC subsets.